Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arbutus Biopharma Cp (ABUS)

Arbutus Biopharma Cp (ABUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 325,201
  • Shares Outstanding, K 84,909
  • Annual Sales, $ 6,010 K
  • Annual Income, $ -153,720 K
  • 60-Month Beta 3.05
  • Price/Sales 40.86
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ABUS with:

Options Overview

Details
  • Implied Volatility 167.66%
  • Historical Volatility 110.43%
  • IV Percentile 40%
  • IV Rank 6.20%
  • IV High 1,017.53% on 03/30/20
  • IV Low 111.52% on 05/21/20
  • Put/Call Vol Ratio 0.09
  • Today's Volume 1,546
  • Volume Avg (30-Day) 2,995
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 41,090
  • Open Int (30-Day) 43,162

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.21
  • Number of Estimates 5
  • High Estimate -0.16
  • Low Estimate -0.25
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.62 +0.55%
on 03/03/21
5.14 -29.18%
on 02/09/21
-0.26 (-6.67%)
since 02/03/21
3-Month
3.40 +7.06%
on 12/09/20
5.87 -37.99%
on 12/15/20
-0.30 (-7.61%)
since 12/03/20
52-Week
0.88 +313.64%
on 04/03/20
9.02 -59.65%
on 07/24/20
+0.85 (+30.47%)
since 03/03/20

Most Recent Stories

More News
Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?

Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ABUS : 3.64 (-4.96%)
Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies...

ABUS : 3.64 (-4.96%)
Thinking about buying stock in GameStop, LivePerson, Etsy, Dynavax Technologies, or Arbutus Biopharma?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, LPSN, ETSY, DVAX, and ABUS.

ABUS : 3.64 (-4.96%)
ETSY : 208.61 (-12.51%)
LPSN : 58.65 (-9.35%)
DVAX : 8.49 (-1.74%)
GME : 124.18 (+5.08%)
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

Trial will evaluate Assembly's core inhibitor candidate, vebicorvir, with Arbutus' RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy

ASMB : 4.88 (-2.20%)
ABUS : 3.64 (-4.96%)
Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies...

ABUS : 3.64 (-4.96%)
NASDAQ, S&P Back at Record Closing Highs

NASDAQ, S&P Back at Record Closing Highs

BOIL : 25.59 (-2.29%)
JNUG : 80.75 (-5.04%)
BG : 78.45 (-1.02%)
AQUA : 24.87 (-2.20%)
AVXL : 13.43 (-3.52%)
DVAX : 8.49 (-1.74%)
ABUS : 3.64 (-4.96%)
DGII : 20.93 (-10.78%)
DAC : 42.35 (+3.80%)
ATEN : 9.51 (-0.42%)
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update

2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs

ABUS : 3.64 (-4.96%)
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies...

ABUS : 3.64 (-4.96%)
Thinking about buying stock in Vistagen Therapeutics, Adapthealth, PainReform, Arbutus Biopharma, or AIM ImmunoTech?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTGN, AHCO, PRFX, ABUS, and AIM.

AIM : 2.26 (-3.42%)
ABUS : 3.64 (-4.96%)
AHCO : 30.49 (-5.07%)
PRFX : 6.55 (-2.96%)
VTGN : 2.32 (-2.93%)
Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV.

ABUS : 3.64 (-4.96%)
ACRS : 21.98 (-5.46%)
MGNX : 23.47 (-4.09%)
RIOT : 49.57 (+0.96%)
MYOV : 22.83 (-5.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 4.07
2nd Resistance Point 3.97
1st Resistance Point 3.81
Last Price 3.64
1st Support Level 3.55
2nd Support Level 3.45
3rd Support Level 3.29

See More

52-Week High 9.02
Fibonacci 61.8% 5.91
Fibonacci 50% 4.95
Fibonacci 38.2% 3.99
Last Price 3.64
52-Week Low 0.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar